Applications of 5'-O-Dimethoxytrityl-N-Benzoyl-Desoxycytidine in Industrial Manufacturing

5'-O-Dimethoxytrityl-N-Benzoyl-Desoxycytidine serves as a specialty protected nucleoside building block in nucleotide synthesis, especially within high-value oligonucleotide and nucleic acid manufacturing sectors. The following application scenarios demonstrate established and compliant industrial practices in which this raw material plays a critical role, each with analyzed process, ratio, standards, and end uses as proven in real production settings.

1. Custom DNA Oligonucleotide Synthesis in Pharmaceutical APIs

Within pharmaceutical API manufacturing, this protected deoxycytidine derivative acts as a fundamental monomer for assembling DNA oligonucleotides via solid-phase synthesis. It ensures controlled incorporation of cytosine units, allowing for selective deprotection without compromising sequence integrity, which is essential for medicinal chemistry programs. Our material supports regulatory compliance for GMP oligonucleotide drug substance manufacturing, fitting tightly specified purity and impurity profile demands.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredient Manufacturing
• US FDA 21 CFR Part 210/211
• European Pharmacopoeia (Ph. Eur.) monographs for nucleotides and oligonucleotides
• USP General Chapter <1045> Biotechnology-Derived Articles

Typical usage ratio

• 0.9–1.05 molar equivalents per coupling step, adjusting per cycle efficiency and desired sequence fidelity

Downstream process integration

• Fed to automated DNA synthesizers at the nucleotide coupling stage following detritylation and oxidation steps
• Used in batch and continuous solid-phase operations on controlled-pore glass (CPG) supports
• Final deprotection achieved with ammonia or methylamine, followed by desalting and purification

Final product types

• Antisense DNA APIs
• siRNA active ingredients
• Therapeutic oligonucleotide leads for clinical trials
• Diagnostic probes for molecular testing kits

2. Diagnostic Oligonucleotide Reagent Production

Specialty manufacturers utilize this protected nucleotide in synthesizing short, sequence-specific DNA probes for use in molecular diagnostics. It enables delivery of high-purity probes required for CE-IVD compliance in PCR, real-time PCR and hybridization-based assays. The protection groups allow for efficient synthesis and downstream deprotection without byproduct contamination, which is essential to ensure probe hybridization accuracy.

Industry compliance standards

• ISO 13485 Quality Management System for Medical Devices
• IVD Directive 98/79/EC (superseded by EU IVD Regulation 2017/746)
• US FDA 21 CFR 820 (QSR) – Medical Devices
• CAP/CLIA Laboratory Validation Requirements

Typical usage ratio

• 0.95–1.10 equivalents per DNA base unit, varied by probe length and synthesis batch size

Downstream process integration

• Employed in phosphoramidite cycle during probe synthesis in small- to medium-scale synthesizers
• Deprotection and purification followed by HPLC or PAGE to achieve high analytical purity required for diagnostic use
• Probes are labeled post-synthesis with fluorescent or affinity tags

Final product types

• Labeled PCR primers and probes
• Hybridization microarray probes
• In situ hybridization (ISH) oligos
• Molecular beacon reagents

3. Research-Grade Deoxycytidine-Containing Oligonucleotide Synthesis

Academic and commercial research facilities depend on this intermediate for synthesizing research-grade oligonucleotides for studies in gene regulation, genome editing, and epigenetics. Its reliable protection profile allows precise control over monomer addition, catering to experimental modifications such as 5-methylcytosine incorporation or custom labeling strategies, ensuring high sequence fidelity even for complex constructs.

Industry compliance standards

• ISO 9001:2015 Quality Management for Research Chemicals
• GLP (Good Laboratory Practice) compliance for regulated studies
• NIH and academic procurement quality requirements

Typical usage ratio

• 1.00 equivalent per nucleotide site; adjustments based on final construct length and labeling strategy

Downstream process integration

• Introduced into synthesizer monomer reservoirs for manual or automated DNA chain elongation
• Used in split-and-pool combinatorial synthesis for oligo library generation
• Cleansed using reverse-phase HPLC for downstream research assays

Final product types

• siRNA and shRNA research tools
• Epigenetic modification study oligos
• Modified DNA libraries for high-throughput screening
• Gene editing donor DNA

4. Nucleotide Analogue Synthesis for Preclinical Studies

Nucleotide analogues, fundamental for investigating DNA polymerase activity, mutagenesis, or PCR chemistry, require precise dC incorporation. The protected form is selected for its compatibility with custom derivatization, such as labeling, cross-linking, or stabilizing modifications. Exacting process control enables downstream users to synthesize modified DNA for biochemical and cellular assays, supporting regulatory submission studies for new molecular entities.

Industry compliance standards

• OECD Good Laboratory Practice for Preclinical Research
• ISO 17025 Laboratory Accreditation for Analytical Quality
• US FDA IND-support material quality guidance

Typical usage ratio

• 0.9–1.0 molar equivalents per synthesis step; optimized to balance yield and modification frequency per experimental design

Downstream process integration

• Integrated in solid-phase phosphoramidite chain assembly workflows
• Allows introduction of non-natural or labeled cytidine units for structure–activity studies
• Processed for analog purification and storage under controlled conditions

Final product types

• DNA analogues for binding assays
• Chain-terminating dideoxy probes
• Base-modified oligonucleotides for mechanistic experiments
• Reference materials for test method validation